ALKERMES PLC (NASDAQ:ALKS) reported second-quarter 2025 financial results that exceeded analyst expectations, driving a notable pre-market rally. The biopharmaceutical company posted revenue of $390.7 million, surpassing the consensus estimate of $348.4 million, while diluted GAAP earnings per share (EPS) of $0.52 also came in ahead of the projected $0.41.
Key Takeaways from the Earnings Report
- Revenue Beat: Alkermes reported Q2 revenue of $390.7 million, a 12.1% increase over analyst estimates. This suggests stronger-than-expected performance across its commercial portfolio, including LYBALVI, ARISTADA, and VIVITROL.
- EPS Surprise: The company delivered GAAP EPS of $0.52, beating estimates by approximately 28%. This indicates improved profitability, likely driven by higher sales and cost management.
- Reiterated Guidance: Alkermes maintained its full-year 2025 financial expectations, signaling confidence in its ability to meet or exceed previously outlined targets.
Market Reaction
The stock surged 7.8% in pre-market trading, reflecting investor optimism following the earnings beat. Despite recent weakness—shares were down 1.9% over the past week and 11.9% over the last two weeks—the strong quarterly results appear to have reversed some of the negative sentiment.
Looking Ahead
Analysts expect Q3 2025 revenue of $360.8 million and full-year sales of $1.412 billion, which Alkermes’ current performance suggests it could meet or exceed. The company’s reiteration of its full-year outlook aligns with these projections, reinforcing stability in its financial trajectory.
For a deeper dive into Alkermes’ earnings and future estimates, visit the earnings estimates page.
Disclaimer: This article is for informational purposes only and does not constitute investment advice.
